Cargando…
Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
SIMPLE SUMMARY: We demonstrate that pro-oncogenic EphA2 (ephrin type-A receptor 2) expression is activated in aggressive prostate cancers, and in mouse models of prostate cancers that are treated with enzalutamide. We also demonstrate in mouse models, that agonistic EphA2 targeting agents are very e...
Autores principales: | Salem, Ahmed F., Gambini, Luca, Billet, Sandrine, Sun, Yu, Oshiro, Hiromichi, Zhao, Ming, Hoffman, Robert M., Bhowmick, Neil A., Pellecchia, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600344/ https://www.ncbi.nlm.nih.gov/pubmed/33023262 http://dx.doi.org/10.3390/cancers12102854 |
Ejemplares similares
-
Reduction of Circulating
Cancer Cells and Metastases
in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug
Conjugate
por: Salem, Ahmed F., et al.
Publicado: (2018) -
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
por: Salem, Ahmed F., et al.
Publicado: (2020) -
Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates
por: Udompholkul, Parima, et al.
Publicado: (2021) -
Targefrin:
A Potent Agent Targeting the Ligand Binding
Domain of EphA2
por: Baggio, Carlo, et al.
Publicado: (2022) -
Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer
por: Thiruvalluvan, Manish, et al.
Publicado: (2022)